Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 7/16/19 (What's New)

Summary

  • Raltegravir and elvitegravir resistance typically evolves over time, with initial patterns replaced by mutations conferring high level resistance if their use is continued[Fransen 2009]
  • Twice-daily doses of dolutegravir have been shown to be effective some of in these patients[Eron 2013]

Action required